To read the full story, subscribe or sign in.

HK growling: Wary plotter Astrazeneca ticks box on safety data pre-$2.7B ZS Pharma buy

Nov. 9, 2015

With the hyperkalemia (HK) space hotter after Astrazeneca plc's $2.7 billion takeover of ZS Pharma Inc. to get the approval-ready ZS-9, eyes of handicappers turned to long-term safety data due at a scientific meeting over the weekend.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Businesspeople shaking hands, meeting with cityscape, charts

Deals and an M&A strengthen end-of-year numbers

BioWorld

Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

BioWorld

Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...